Hangzhou Rossen

Rossen Biotech is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the development of innovative small molecule therapeutics for metabolic diseases and oncology. The company leverages a proprietary medicinal chemistry platform, with a core focus on deuterium substitution technology, to optimize the metabolic stability and safety profiles of drug candidates. Its lead program, RSN-011, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Rossen Biotech aims to address significant unmet medical needs by developing best-in-class therapies with improved clinical outcomes compared to existing standards of care.